In fact, it was reported that most if not all LGLL patients display constitutive expression of FasL gene transcripts and that leukemic cells from 90% of T-LGLL patients express both Fas (CD95) and FasL (CD178) at high levels, nonetheless being completely resistant to anti-Fas- and anti-CD3-mediated apoptosis. The gene discussed is FAS; the disease is T-cell large granular lymphocyte leukemia.